Seattle Startup Oisín Biotechnologies Raises Cash to Develop Therapies for Age-Related Diseases

Oisín Biotechnologies, a Seattle-based startup focused on treating aging-related diseases, raised the first close of a $15 million Series A round. The company is developing preclinical therapies to eliminate unwanted fat cells and build muscle mass to address frailty.

Oisín was founded in 2016 by Matthew Scholz, Oisín’s CEO, along with John Lewis, chief science officer, and Gary Hudson, chairman. Scholz is also CEO of OncoSenX, which spun out of Oisín in 2018 and is studying the treatment of solid tumors. AbbVie Ventures led the first close.